Article
Immunology
Shiyu Zhang, Jiajia Du, Xin Zhong, Ping Tan, Hang Xu, Jiapeng Zhang, Di Jin, Yifan Li, Weizhen Le, Xingyu Xiong, Tianhai Lin, Qiang Wei
Summary: This study aimed to evaluate the association of preoperative systemic immune-inflammation index (SII) with the clinical outcomes of patients diagnosed with bladder cancer and who underwent radical cystectomy (RC). The study found that a high SII level was associated with worse overall survival and recurrence-free survival.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Yong-Wei Huang, Xiao-Shuang Yin, Zong-Ping Li
Summary: The novel systemic immune-inflammation index (SII) has been associated with clinical outcomes in stroke patients, showing significant correlations with poor outcomes, mortality, and hemorrhagic transformation, but no impact on recanalization. Patients with high SII levels are more likely to experience adverse outcomes and death in stroke cases.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Ye Qiu, Zongxin Zhang, Ying Chen
Summary: By conducting meta-analysis, this study found that a high pretreatment SII is associated with poor overall survival in gastric cancer patients and several clinical characteristics. Monitoring SII could be valuable for guiding prognostication in GC.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Yan Wang, Qunqin Ni
Summary: This meta-analysis investigates the prognostic value of the systemic immune-inflammation index (SII) among carcinoma patients treated with immune checkpoint inhibitors (ICIs). The results show that elevated SII is significantly associated with poor survival outcomes among ICI-receiving carcinoma patients. SII has the potential to be a reliable and cost-effective prognostic biomarker in clinical settings.
ANNALS OF MEDICINE
(2023)
Article
Oncology
Alessandro Bittoni, Federica Pecci, Giulia Mentrasti, Sonia Crocetti, Alessio Lupi, Andrea Lanese, Chiara Pellei, Chiara Ciotti, Luca Cantini, Riccardo Giampieri, Edoardo Lenci, Enrica Giglio, Federica Bini, Cecilia Copparoni, Tania Meletani, Maria Giuditta Baleani, Rossana Berardi
Summary: Elevated systemic immune-inflammation index (SII) was found to be an independent negative prognostic factor for both overall survival (OS) and progression-free survival (PFS) in advanced pancreatic ductal adenocarcinoma (PDAC) patients undergoing first-line chemotherapy, highlighting the crucial role of systemic inflammation in PDAC progression and patient outcomes.
ANNALS OF TRANSLATIONAL MEDICINE
(2021)
Review
Medicine, Research & Experimental
Linghao Meng, Yujia Yang, Xu Hu, Ruohan Zhang, Xiang Li
Summary: A systematic review and meta-analysis found that a high systemic immune-inflammation index (SII) is associated with poor prognosis in prostate cancer patients. This suggests that SII may serve as an important prognostic indicator in patients with prostate cancer.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Review
Medicine, General & Internal
Wei Cao, Yifeng Shao, Shangzhang Zou, Na Wang, Jinguo Wang
Summary: A meta-analysis was conducted to evaluate the prognostic role of Systemic Immune-inflammation Index (SII) in bladder cancer. The findings indicated that higher levels of pretreatment SII were significantly associated with poorer survival rates in bladder cancer patients, suggesting that SII is an important predictor of prognosis in bladder cancer patients.
Article
Medicine, Research & Experimental
Mao Li, Zhenlu Li, Zihe Wang, Chao Yue, Weiming Hu, Huimin Lu
Summary: This meta-analysis evaluated the prognostic impact of the systemic immune-inflammation index (SII) in patients with pancreatic cancer (PC) and found that high SII was associated with poor survival rates. Therefore, SII may serve as a cost-effective biological marker for monitoring the survival of PC patients.
CLINICAL AND EXPERIMENTAL MEDICINE
(2022)
Article
Cell Biology
Yifang Shui, Mengquan Li, Jing Su, Mingxun Chen, Xiaobin Gu, Wenzhi Guo
Summary: This meta-analysis indicates that elevated SII is significantly associated with poor prognosis in patients with pancreatic cancer, including OS, RFS/PFS/DFS, and CSS, while showing no significant correlation with other clinicopathological parameters.
Review
Medicine, Research & Experimental
Junyan Kou, Jing Huang, Jun Li, Zhen Wu, Liwei Ni
Summary: The systemic immune-inflammation index (SII) is associated with prognosis in cancer patients receiving immunotherapy, and a high level of SII may indicate poor prognosis in advanced cancer patients treated with immunotherapy.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Review
Clinical Neurology
Sunhuan Zhang, Qunqin Ni
Summary: This meta-analysis found that an increased SII level is associated with poor overall survival and progression-free survival in glioma patients. Additionally, a high SII value is correlated with a Ki-67 index of >= 30%.
FRONTIERS IN NEUROLOGY
(2023)
Article
Medicine, General & Internal
Chao Yang, Bo-Wen Hu, Feng Tang, Qing Zhang, Wei Quan, Jie Wang, Ze-Fen Wang, Yi-Rong Li, Zhi-Qiang Li
Summary: Inflammation is closely linked to cancer, and the systemic immune-inflammation index (SII) has been shown to have prognostic value in various types of cancer. This study specifically focused on glioblastoma (GBM) patients and found that a higher SII was associated with poorer overall survival. The integration of SII-NLR score in a nomogram showed promising predictive power for survival outcomes in GBM patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Fangqiu Fu, Zhendong Gao, Zhexu Wen, Zhendong Gao, Yue Zhao, Han Han, Shanbo Zheng, Shengping Wang, Yuan Li, Hong Hu, Yang Zhang, Haiquan Chen
Summary: This study identified that the systemic immune-inflammation index (SII) is independently associated with prognosis in patients with non-small cell lung cancer (NSCLC), especially in patients with stage I disease, solid nodules, and adenocarcinoma. The findings help to specify the target population for clinical use of SII.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Review
Oncology
Yuting Zhou, Menglu Dai, Zongxin Zhang
Summary: This meta-analysis investigated the prognostic and clinicopathological significance of the systemic immune-inflammation index (SII) in small cell lung cancer (SCLC). The results showed that a high SII was significantly associated with worse overall survival (OS) but not progression-free survival (PFS) in SCLC patients. A high SII was also associated with extensive-stage SCLC. However, there was no significant correlation between SII and age, sex, smoking history, Karnofsky Performance Status score, or initial therapeutic response.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Xue-chun Liu, Yue-ping Jiang, Xue-guo Sun, Jian-jian Zhao, Ling-yun Zhang, Xue Jing
Summary: This meta-analysis investigated the prognostic value of preoperative SII in patients with cholangiocarcinoma (CCA). The results showed that a higher preoperative SII is associated with poor overall survival in patients with CCA who underwent invasive surgery. These findings suggest that preoperative SII could be an effective method for monitoring survival in CCA patients.
FRONTIERS IN ONCOLOGY
(2022)